Sotatercept Winrevair News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.

Matt granatoSotatercept winrevairAaron waxmanWorld health organizationPulmonary hypertension associationThenew england journalPulmonary heart diseasesPulmonary arterial hypertension symptomsPhysical impactsCardiopulmonary symptomsEmotional impacts